premenopausal metastatic breast cancer
Conditions
Interventions
a combination of a gonadotropin-releasing hormone agonist goserelin or Leuprorelin Acetate, and a high-dose toremifene until disease progression.
Sponsors
Multi Hormone Study Group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: premenopausal women with metastatic or locally advanced breast cancer who had previously been treated with gonadotropin-releasing hormone agonist and tamoxifen or aromatase inhibitor
Exclusion criteria
Exclusion criteria: Patients have an inadequte organ function. Patients who have had any previous or concomitant malignancy. Patients who have had any other non-malignant systemic diseases (cardiovascular, renal lung, etc. ) that would prevent follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Benefit | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical response rate Time to progression Time to treatment failure adverse events | — |
Countries
Japan
Contacts
Public ContactNobuaki Sato
Niigata Cancer Center Hospital Department of Surgery
Outcome results
None listed